Bayer's Portfolio Overhaul and the Missouri Verdict That Could Unlock a 70-Euro Case

Bayer shares closed at EUR 50.20, up 36% this year, as a $7.25 billion Roundup settlement awaits a Missouri judge's approval.

Two forces are pulling at Bayer's investment story right now, and they run on very different clocks. One is a steady, deliberate reshaping of the company's asset base — asset sales, capital raises, pipeline rollouts. The other is a single courtroom in Missouri, where the German group's most stubborn legal overhang may finally be capped.

The stock closed Friday at EUR 50.20, up 36% since the start of the year. That gain has been built partly on operational news and partly on the market's cautious bet that the worst of the glyphosate litigation is behind it.

A Settlement Waiting on a Judge's Signature

Roughly two weeks ago, Monsanto appeared before a Missouri judge seeking approval of a $7.25 billion settlement designed to resolve nearly all existing and future U.S. cancer claims tied to Roundup. No immediate ruling was handed down at that hearing — but the shares have climbed 3.0% since it took place, a sign that investors read the procedural step as progress.

Reuters has described the settlement as the single largest burden still weighing on Bayer. A judicial green light would put a fixed ceiling on liabilities that currently stem from tens of thousands of individual cases, replacing open-ended risk with something the market can actually price. Until that signature arrives, the legal question remains the dominant factor in how the company is valued.

Barclays and Deutsche Bank See Room Above the Current Price

Analysts have responded to the legal maneuvering with measured optimism. Barclays lifted its target to EUR 70.00 on September 8 while keeping a positive rating — implying meaningful upside if the litigation knot comes undone. Deutsche Bank, according to media reports, reaffirmed its EUR 60.00 target on September 10, and other institutional houses published targets above the current quote in early September.

How quickly those targets become realistic depends heavily on the pace at which remaining legal uncertainty is cleared. While the U.S. approval is pending, the market continues to price in caution. A durable end to the disputes could open the door to a re-rating.

Stivarga Sale Adds to a Growing List of Portfolio Moves

Bayer's operational housekeeping has continued in parallel. The agreed sale of cancer drug Stivarga to Grünenthal, sealed on September 21, will bring in up to EUR 375 million. The deal covers regorafenib, which will move into Grünenthal's portfolio, and marks Bayer's exit from an established oncology asset as it sharpens its focus on core areas. Completion depends on regulatory approvals and is targeted for late 2026 or early 2027.

On the same front, the company introduced a polypropylene mono-material blister pack for Talcid in Germany on Wednesday, with a phased rollout planned across eleven more European countries. In agriculture, Leaps by Bayer led a Series A financing round on September 17 for Robigo, a developer working on biological crop protection. Crop Science, meanwhile, is pushing ahead with the global launch of its integrated seed-and-crop-protection pipeline, including systems such as Plenexos and the Preceon Smart Corn System.

Balance Sheet Gets Three Fresh Injections

The Stivarga disposal slots into a broader sequence of financial moves. Apollo and KKR completed a capital solution for Bayer, committing EUR 3 billion in equity for a new unit bundling long-acting reversible contraceptives. Bayer retains a majority stake and continues to run the operation.

Separately, the group issued EUR 2 billion in hybrid bonds to shore up liquidity for general corporate purposes, lifting its outstanding hybrid volume to EUR 6.55 billion. On the shareholder side, French asset manager Amundi reported on September 14 that its voting rights in Bayer had crossed the notification threshold, now standing at 3.04%.

What Has to Happen Next

The gap between the current EUR 50.20 and the targets published by Barclays and Deutsche Bank rests largely on one question: whether the U.S. judiciary signs off on the $7.25 billion settlement and gives Bayer the planning certainty it has been chasing. Until then, the portfolio work — the Stivarga sale, the contraceptive joint venture, the hybrid issuance, the pipeline launches — proceeds on its own schedule, steadily narrowing what the company is and what it is betting on.